Navigation Links
VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
Date:8/25/2008

BOSTON, Aug. 25 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP), entitled, "Creating Value; Turnaround Leverages Product Opportunities while Expectation Abounds and Losses Decrease."

This review is available at website: http://www.scimitarequity.com

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment of dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT: Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
11. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 24, 2016 , ... Last week, Callan Capital, an integrated wealth management firm ... Future of San Diego Life Science event at the Estancia La Jolla Resort and ... event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine ... experienced veterinary clients have treated over 100 of their own patients with the VetStem ... the highest level of care for their patients. , The veterinarians are Dr ...
(Date:5/19/2016)... 19, 2016  AdvancedFlow Systems Inc. (AFS), a ... out of Maple Ridge, British Columbia ... its existing portfolio of contract manufacturing clients by ... with its sister companies Surround Technologies (STI) and ... industrial group that specializes in providing contract manufacturing ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/15/2016)... 2016 --> --> ... Market Research "Digital Door Lock Systems Market - Global Industry ... the global digital door lock systems market in terms of ... is forecast to grow at a CAGR of 31.8% during ... medium enterprises (MSMEs) across the world and high industrial activity ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):